ISIN | LU0942225912 |
---|---|
Valor Number | 21612660 |
Bloomberg Global ID | |
Fund Name | Candriam Equities L Biotechnology R-Acc |
Fund Provider |
CANDRIAM
Serenity, Bloc - B, 19-21, route d'Arlon 8009 Strassen E-Mail: CH@Candriam.com Phone: + 352 2797-1 Web: https://www.candriam.com |
Fund Provider | CANDRIAM |
Representative in Switzerland |
CACEIS (Switzerland) SA Nyon Phone: +41 22 360 94 00 |
Distributor(s) | |
Asset Class | Bonds |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund. |
Peculiarities |
Current Price * | 295.48 USD | 01.08.2024 |
---|---|---|
Previous Price * | 295.70 USD | 31.07.2024 |
52 Week High * | 300.84 USD | 16.07.2024 |
52 Week Low * | 213.45 USD | 27.10.2023 |
NAV * | 295.48 USD | 01.08.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,640,774,982 | |
Unit/Share Assets *** | 174,941,421 | |
Trading Information SIX |
YTD Performance | +12.86% |
29.12.2023 - 01.08.2024
29.12.2023 01.08.2024 |
---|---|---|
YTD Performance (in CHF) | +17.12% |
29.12.2023 - 01.08.2024
29.12.2023 01.08.2024 |
1 month | +6.31% |
01.07.2024 - 01.08.2024
01.07.2024 01.08.2024 |
3 months | +13.49% |
02.05.2024 - 01.08.2024
02.05.2024 01.08.2024 |
6 months | +9.77% |
01.02.2024 - 01.08.2024
01.02.2024 01.08.2024 |
1 year | +22.99% |
01.08.2023 - 01.08.2024
01.08.2023 01.08.2024 |
2 years | +35.93% |
01.08.2022 - 01.08.2024
01.08.2022 01.08.2024 |
3 years | +18.53% |
02.08.2021 - 01.08.2024
02.08.2021 01.08.2024 |
5 years | +69.56% |
01.08.2019 - 01.08.2024
01.08.2019 01.08.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Regeneron Pharmaceuticals Inc | 6.96% | |
---|---|---|
Vertex Pharmaceuticals Inc | 6.16% | |
Amgen Inc | 5.68% | |
Alnylam Pharmaceuticals Inc | 4.94% | |
Gilead Sciences Inc | 4.30% | |
Biogen Inc | 3.62% | |
Moderna Inc | 3.53% | |
Eli Lilly and Co | 3.27% | |
Biomarin Pharmaceutical Inc | 2.74% | |
Incyte Corp | 2.49% | |
Last data update | 30.06.2024 |
TER | |
---|---|
TER date | |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.10% |
SRRI ***
|
|
SRRI date *** | 30.06.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |